Dr. Wiesława Dominika Wranik (Principal Investigator) is an Associate Professor at the School of Public Administration at Dalhousie University, a health economist and health policy researcher. Her research focuses on the use of economic, clinical and other information by health policy makers. For example, she led a study exploring how economic evidence is used by members of the Nova Scotia Cancer Systemic Therapy Committee, on which she had been an active member from 2006 to 2011. Since 2018, she is a member of the pCODR Expert Review Committee, and has previously worked as a Lead for the pCODR Economic Guidance Panel. She has collaborated in her research with public sector decision makers, including pCODR, Health Canada, the Public Health Agency of Canada, the Nova Scotia Department of Health and Wellness, Manitoba Health, and Alberta Health.
Dr. Jeffrey Hoch (Co-Principal Investigator) is a Professor at the Department of Health Sciences and Associate Director for the Centre of Health Care Policy and Research and the University of California Davis. Dr. Hoch has been intimately involved in the conceptualization, design and implementation of pCODR. Dr. Hoch has published on the use of economics and comparative effectiveness research in drug funding decisions, and has also produced numerous applied health economic analyses of cancer therapies to support pCODR.
Dr. Adrian Levy (Co-Principal Investigator) is a Professor and Head of the Department of Community Health and Epidemiology at Dalhousie University, and District Chief with the Capital District Health Authority. He is an epidemiologist and health services researcher, with a focus on the allocation of resources within the health care system. Dr. Levy has worked collaboratively with a variety of stakeholders across Canada, as both academic researcher and administrator.
Mona Sabharwal, BScPhm, PharmD, R.Ph (Primary Knowledge User) is the inaugural executive director of the pan-Canadian Oncology Drug Review (pCODR). She has worked in drug technology assessment and formulary management, in both British Columbia and Ontario, for more than 15 years. Before joining pCODR, she was the Senior Manager for Drug Programs Management with the Ontario Ministry of Health and Long-Term Care. In this role, she had operational oversight of the drug submission and evaluation process for Ontario's seven public drug programs. During her time at the Ministry, Dr. Sabharwal was a key participant in the early development of pCODR and led operations for its precursor, the interim Joint Oncology Drug Review (iJODR). She was also instrumental in Ontario's development of a new and innovative evaluation framework for Drugs for Rare Diseases, implemented in 2008. In 2010, she spear-headed and launched Ontario's patient-evidence submission process, a formal process to systematically solicit patient-centred perspectives on new drug therapies.
Dr. Chris Skedgel (Co-Investigator) is a Senior Lecturer in Applied Health Economics at the University of East Anglia. Until recently, he was a member of the pCODR Economic Review Committee. He is a co-Investigator with AFFORD. His primary research interests are around maximizing the value of limited healthcare resources, including economic efficiency and the broader concepts of societal value. His methodological expertise includes stated preference methods, health economic decision modelling, administrative data analysis, and model-based cluster analysis. His role in this project will be to ensure that the project remains relevant to pCODR, specifically to the use of economic evidence in the formulary process.
Dr. Tallal Younis (Co-Investigator) received his medical degree from Cairo University in 1992. He completed an internal medicine residency in 2001 at Columbia University, New York, and a Medical Oncology Fellowship in 2003 at the Roswell Park Cancer Institute, State University of New York at Buffalo. He is currently a medical oncologist at the Queen Elizabeth II Health Sciences Centre in Halifax, with a clinical practice focused on breast cancer. He is a co-chair of the Nova Scotia provincial breast site team, and a member the Pan Canadian Oncology Drug Review – Expert Review Committee (pCODR – ERC) as well as both the clinical and research advisory groups of the Canadian Partnership Against Cancer (CPAC). He is an associate professor of Medicine, and a clinical research scholar, at Dalhousie University. His research interests involve health economics and health services research in breast cancer. He has been an editor for the medical oncology section in Current Oncology since 2013.
Dr. Liesl Gambold (Co-Investigator) is an Assistant Professor at the Department of Sociology and Social Anthropology, Dalhousie University. Dr. Gambold teaches classes on qualitative research methods, research design, gender, and the life course. Dr. Gambold's current research focuses on decision-making among retirees about migration and mobility. She recently led the qualitative data collection and analysis on the ARCC pilot project exploring how economic evidence is used by members of the Nova Scotia Cancer Systemic Therapy Committee.
Dr. Mark Dobrow (Co-investigator) is an Associate Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. Dr. Dobrow’s research interests focus on improving the understanding and use (e.g., identification, interpretation and application) of different types of evidence (e.g., research, contextual and experiential) to inform health policy decisions, with a primary focus on cancer systems and policy. Dr. Dobrow’s research has been informed by leadership roles at both national and provincial health care agencies, including a secondment as Vice-President of Health System Performance at Health Quality Ontario, Director of Analysis and Reporting at the Health Council of Canada, and Scientist and Lead of the Cancer Services and Policy Research Unit at Cancer Care Ontario.
Dr. Stirling Bryan (Collaborator) is a Professor at the Department of Medicine at the University of British Columbia, the Director of the Centre for Clinical Epidemiology and Evaluation at Vancouver Coastal Health, and an Adjunct Associate with the Research Institute and Stanford Health Policy.
Min Hu M.A., (Research Assistant), is currently a PhD student in Economics of Dalhousie University. His research filed is Applied Microeconomics, Health Economics, Labour Economics and Data Mining. He has been involved in economics research with Dalhousie University, the Research Data Center of Statistic Canada, and Diamond Bank.